Pharmacyclics, Inc. (PCYC) announced updated results from two clinical trials of Bruton's tyrosine kinase, or BTK, inhibitor, ibrutinib (PCI-32765), for treating patients with chronic lymphocytic leukemia, or CLL,/small lymphocytic lymphoma, or SLL.
The ibrutinib clinical updates released in two oral presentations include - 1) updated safety and efficacy data from the Phase Ib/II CLL/SLL single agent trial (PCYC-1102); and 2) updated safety and efficacy data from the Phase Ib/II CLL/SLL combination trial with bendamustine and rituximab in relapsed or refractory patients (PCYC-1108).
Updated results of PCYC-1102 trial showed that the BTK inhibitor Ibrutinib (PCI-32765) is highly active and tolerable in relapsed or refractory and treatment naive chronic lymphocytic leukemia patients.
In PCYC-1108, 37% were considered refractory to a purine analog containing regimen and 13% refractory to bendamustine. There have been no discontinuations due to adverse events. With a median follow up of 8.1 months, only 2 patients have reported progressive disease and an additional 5 patients have proceeded to stem cell transplant, 23 (77%) of patients remain on study.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.